Kinetics of diabetes-associated autoantibodies after sequential intraportal islet allograft associated with kidney transplantation in type I diabetes

Diabetes and Metabolism

Volumn 29, Issue 6, 2003, Pages 595-601

  Vantyghem, M C ^a,c   Fajardy, I ^b   Pigny, P ^b   Noel, C ^b   Kerr Conte, J ^a   Gmyr, V ^a   Vandewalle, B ^a   Proye, C ^b   Pattou, F ^a  

^a INSERM   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Dept of Endocrinol and Metabolism ^*  (France)

Author keywords

Islet transplantation; Pancreas autoantibodies; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; CYCLOSPORIN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; HLA ANTIGEN CLASS 2; INSULIN ANTIBODY; MYCOPHENOLIC ACID; PANCREAS ISLET CELL ANTIBODY; STEROID; UNCLASSIFIED DRUG;

ADULT; ALLOGRAFT; ANTIBODY PRODUCTION; ARTICLE; CASE REPORT; GRAFT REJECTION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MALE; PANCREAS ISLET TRANSPLANTATION; PHENOTYPE; PROGNOSIS;

EID: 0346493005     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70074-5     Document Type: Article

References (25)

1. Shapiro AMJ, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type I diabetes. N Engl J Med, 2000, 34, 230-8.
2. Eisenbarth GS, Stegall M. Islet and pancreatic transplantation-autoimmunity and alloimmunity. N Engl J Med, 1996, 19, 888-90.
3. Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation, 1996, 61, 1272-4.
4. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody negative IDDM recipients of intrahepatic islet allografts. Diabetes, 1997, 46, 1907-10.
5. Jaeger C, Hering BJ, Hatziagelaki E, Federlin K, Bretzel RG. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted DDM patients and persist or occur despite immunosuppression. J Mol Med, 1999, 77, 45-8.
6. Keymeulen B, Ling Z, Gorus FK, et al. Implantation of standardized-cell grafts in a liver segment of IDDM patients: graft and recipient characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft. Diabetologia, 1998, 41, 452-9.
7. Roep BO, Stobbe I, Duinkerker G, et al. Auto-and alloimmune reactivity to human islet allografts transplanted into type I diabetic patients. Diabetes, 1999, 48, 484-90.
8. Bosi E, Braghi S, Maffi P, et al. Autoantibody response after islet transplantation in type 1 diabetes. Diabetes, 2001, 50, 2464-71.
9. Morsiani E, Cappellari L, Fogli L, Ricci D, Puviani C, Azzena G. Xenograft of piscine insular tissue in nude streptozotocin-diabetic mice: a transplantation model. Transplant Proc, 1992, 24, 672-3.
10. Pattou F, Vantyghem MC, Noel C, et al. Sequential intraportal islet allografts in immunosuppressed type I diabetic patients: preliminary results. Transplant Proc, 2000, 32, 391-2.
11. Ricordi C, Rastellini C. Automated method for pancreatic islet separation. Ricordi C Ed. Methods in cell transplantation. Austin, RG, Landes 1995,433-8.
12. Dono K, Gotoh M, Wang K, et al. Sequential multiple donor islet transplantation: a model for repeated transplantation into the portal system in dogs. Transplant Proc, 1991, 23, 770-1.
13. International Islet Transplant Registry, 2001, 8, 18.
14. Urakami T, Miyamoto Y, Matsunaga H, Owada M, Kitagawa T. Serial changes in the preavalence of islet cell antibodies and islet cell titer in children with IDDM of abrupt or slow onset. Diabetes Care, 1995, 18, 1095-9.
15. Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell autoantibodies) in type 1 diabetes; Combinatorial islet autoantibody workshop. Diabetes, 1998, 47, 1857-66.
16. Hermitte L, Atlan-Gepner C, Mattei C, et al. Diverging evolution of anti-GAD and anti-IA2 antibodies in long-standing diabetes mellitus as a function of age at onset: no association with complications. Diabetic Medicine, 1998, 15, 586-91.
17. Bach JF. Insulin-dependant diabetes mellitus as an autoimmune disease. Endocrine Reviews, 1994, 15, 516-42.
18. Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependancy in children with recent onset type 1 diabetes treated with low-dose of cyclosporin. Diabetes, 1990, 39, 1264-72.
19. Thivolet C, Abou-Amara S, Martin X, et al. Serological markers of recurrent β cell destructionin diabetic patients undergoing pancreas transplantation. Transplantation, 2000, 69, 99-103.
20. Christie MR, Molvig J, Hawkes CJ, et al. IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type I diabetic patients treated with cyclosporin Diabetes Care, 2002, 25, 1192-7.
21. Komulainen J, Kulmala P, Savola K, et al. Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Diabetes Care, 1999, 22, 1950-5.
22. Brooks-Worrell BM, Peterson KP, Peterson CM, Palmer JP, Jovanovic L. Reactivation of type I diabetes in patients receiving human foetal pancreatic tissue transplant without immunosuppression. Transplantation, 2000, 69, 1824-9.
23. Shapiro AM, Suarez-Pinson WL, Power R, Rabinovitch A. Combination therapy with low dose sirolinius and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese-diabetic mice. Diabetologia, 2002, 45, 224-40.
24. Shapiro AM, Hao EG, Lakey JR, et al. Novel approaches toward early diagnosis of islet allograft rejection. Transplantation, 2001, 71, 1709-18.
25. Caillat-Zucman S, Garchon HJ, Timsit J, et al. Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus. J Clin Invest, 1992, 90, 2242-50.